Rekombinanter TAG-72 (Satumomab Biosimilar) Antikörper

Produktnummer ABIN7795125

Der Human Monoklonal anti-TAG-72 (Satumomab Biosimilar) Antikörper wird verwendet zum Nachweis von TAG-72 (Satumomab Biosimilar) in Proben von Human. Er wurde validiert für FACS und in vivo.

Kurzübersicht für Rekombinanter TAG-72 (Satumomab Biosimilar) Antikörper (ABIN7795125)

Target: TAG-72 (Satumomab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Human

Klonalität: Monoklonal

Konjugat: Dieser TAG-72 (Satumomab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-TAG-72 (Satumomab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Satumomab Biosimilar, Anti-human TAG-72 Monoclonal Antibody

Produktmerkmale: Satumomab Biosimilar uses the same protein sequences as the therapeutic antibody satumomab. Satumomab is a modified mouse monoclonal antibody which could specifically bind to tumor-associated glycoprotein (TAG-72). Satumomab is usually combined with some radioactive elements to diagnose colorectal cancer and ovarian cancer. Satumomab is also used to study the distribution of tumor cell-associated antigens in breast cancer. The original satumomab monoclonal antibody was produced by purifying the membrane enrichment part of human breast cancer biopsy tissue and immunizing mice. In fact, in addition to colorectal and ovarian cancer, satumomab can also interact with a variety of cancer cells, including gastric cancer, pancreatic cancer, endometrial cancer and lung adenocarcinoma. For a variety of normal adult tissues, except secretory endometrium, B72.3 had no effect or only weak response. The characteristic that satumomab can bind to tumor antigen TAG-72 has been used in the clinical study of various cancer detection. Serological tests used satumomab showed that 50 % of cancer patients could be detected TAG-72 and 4 % of the control population could be detected TAG-72. Satumomab is also used to detect embryonic carcinoma and fine needle biopsy in human effusion and as a diagnostic tool to distinguish lung adenocarcinoma from non-small cell lung cancer or malignant mesothelioma. Labeled satumomab-assisted computer scanning is used to study the localization of tumor lesions. The target of satumomab, TAG-72, is a kind of tumor marker with high specificity and few false positive. Because TAG-72 widely exists in all kinds of cancer tissues and has little expression in normal and benign lesions, anti-TAG-72 monoclonal antibody, which uses satumomab as substitute, has been applied to the study of immunohistochemistry and immunocytochemistry. Those monoclonal antibodies have become a useful tool for clinical tumor diagnosis and differential diagnosis.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human TAG-72

Isotyp: IgG1, kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Details zu TAG-72 (Satumomab Biosimilar)

Target: TAG-72 (Satumomab Biosimilar)

Andere Bezeichnung: Satumomab Biosimilar

Substanzklasse: Biosimilar